The analysis indicated that the pharmacodynamic differences might be linked to pathways such as the PI3K/Akt signaling pathway, insulin signaling pathway, nonalcoholic fatty liver disease, TNF signaling pathway, and FoxO signaling pathway. The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatotic liver disease.